Medications

April 26, 2019 The FDA has approved Eticovo (etanercept-ykro), a biosimilar to U.S.-licensed Enbrel (etanercept).

A biosimilar product is a biological product that is approved based on a showing that it is highly similar to an already-FDA approved biological product, known as a reference product. The biosimilar also must be shown to have no clinically meaningful differences in terms of safety and effectiveness from the reference product.

Posted: April 2019

Eticovo (etanercept-ykro) FDA Approval History

Source: Read Full Article

Related posts:
  1. FDA Approves Elzonris (tagraxofusp-erzs), the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted Therapy
  2. FDA Approves Ultomiris
  3. Don’t suddenly stop taking a prescribed opioid, FDA warns
  4. A new molecule to improve treatment for type 2 diabetes and non-alcoholic fatty liver disease